It´s important to note that future iterations of AlzyFinder could benefit from the integration of more sophisticated network pharmacology analyses, including the exploration of protein-protein interactions and the impact of polypharmacology on therapeutic outcomes. This would provide a more holistic view of how potential drug candidates interact within biological systems, paving the way for the development of more effective and targeted therapeutic strategies. By enabling researchers worldwide to independently analyze and validate their findings, AlzyFinder not only democratizes the drug discovery process but also contributes to the collective effort to combat Alzheimer's disease. In summary, the AlzyFinder Platform stands as a valuable resource for the AD research community, setting a new standard for open-access tools in biomedical research. Its innovative integration of machine learning and network pharmacology opens new avenues for investigating the intricate mechanisms underlying AD, ultimately leading to the development of more effective therapeutic strategies.